| $385M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $ | – | |
Sells | $ | – |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Over the last 12 months, insiders at GlycoMimetics, Inc. have bought $undefined and sold $undefined worth of GlycoMimetics, Inc. stock.
On average, over the past 5 years, insiders at GlycoMimetics, Inc. have bought $1.25M and sold $4.46M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 115,000 shares for transaction amount of $30,717 was made by Rock Edwin (Chief Medical Officer) on 2024‑06‑21.
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |